1. Introduction {#sec1}
===============

With the increase of life expectancy our societies experience comes a slew of age-related diseases. The aging process is characterized for instance by changes in body composition that include a decrease in muscle mass and/or strength. This manifestation of aging known as muscle wasting [@bib1], [@bib2], is a cause of a metabolic deregulation [@bib3], [@bib4], and also contributes to the increased morbidity seen in the elderly because of the higher risk of falls and fractures. One of the proposed causes for this age-related decline in muscle mass is a reduced muscle protein turnover, defined as the balance between muscle protein synthesis and breakdown [@bib5]. How protein turnover in muscle is regulated and can be affected by aging remains however, poorly understood. The recent demonstration that the bone-derived hormone osteocalcin favors muscle functions during exercise [@bib6], [@bib7] raises the question of whether this hormone may also regulate muscle mass.

In support of this working hypothesis we note that osteocalcin favors physiological functions that like testosterone synthesis and male fertility [@bib8], [@bib9], memory or adaptation to exercise [@bib7], [@bib10], tend to decrease with age. At the same time the circulating levels of bioactive osteocalcin decrease rapidly and steeply in life in mice, monkeys and humans [@bib7]. These findings were two additional incentives to ask whether osteocalcin signaling in myofibers also prevents another aspect of aging namely the decrease in muscle mass. Here we show that osteocalcin signaling in myofibers is necessary to maintain muscle mass in older mice because it promotes protein synthesis in muscle cells. More importantly, exogenous osteocalcin is also sufficient to increase muscle mass in 10-month-old mice. These results expand the importance of the regulation of muscle physiology by bone-derived hormones and suggest novel and adapted therapies to treat age-related muscle wasting.

2. Materials and methods {#sec2}
========================

2.1. Animal studies {#sec2.1}
-------------------

*Osteocalcin* (*Ocn*−/−) mice were maintained on 129-Sv genetic backgrounds. *Gprc6a*−/−, *Gprc6a*~*Mck*~−/− and *Ocn*+/−;*Gprc6a*~*Mck*~+/− mice were maintained on 129-Sv/C57/BL6 mixed genetic background. To minimize the possible confounding effect of a different genetic background all experiments were performed using control littermates. Generation of mice harboring a *Gprc6a* conditional allele has been described [@bib9]. For osteocalcin treatment studies 9-month-old WT 129-Sv mice (Taconic) were implanted with subcutaneous osmotic pumps (Alzet, model 1004) delivering osteocalcin (90 ng/h) for 28 days. After this period, mice were euthanized and muscles dissected for analyses of muscle mass and histology examination. Recombinant osteocalcin was purified as previously described [@bib10]. All procedures involving mice were approved by CUMC IACUC and conform to the relevant regulatory standards.

2.2. Histology {#sec2.2}
--------------

Examination of muscle histology was done using 5-μm thick formalin-fixed, paraffin-embedded tissue sections stained with hematoxylin and eosin (H&E) at the Molecular Pathology Core at UT Southwestern Medical Center.

2.3. Myoblasts culture and differentiation {#sec2.3}
------------------------------------------

Culture of mouse skeletal muscle myoblasts was performed as described [@bib7], [@bib11], using 15- to 20-day-old mice. Myoblasts were cultured until 80% confluent and then differentiated into myotubes in DMEM supplemented with 5% horse serum.

For in vitro inactivation of *Gprc6a*, myoblasts from *Gprc6a*−/− mice and WT controls were isolated and differentiated as above.

2.4. Protein synthesis {#sec2.4}
----------------------

Protein synthesis was determined as the incorporation of ^3^H-tyrosine to cellular proteins. In brief, myotubes were differentiated for 4 days in 24-well plates. The day of the experiment cells were washed and incubated in serum free-high glucose DMEM 0.1% BSA for 4 h. Next, 2 μCi/well of ^3^H-tyrosine with either vehicle or osteocalcin were added to each well. Cells were then incubated for 2 h following 2 washes with 1× PBS. Next, cellular proteins were precipitated with 10% TCA and radioactivity measured in the precipitated fraction. Results were corrected using the protein concentration in each well.

2.5. Western blot {#sec2.5}
-----------------

To detect total and phosphorylated mTOR, S6K1, Raptor and GAPDH proteins were resolved on 8% acrylamide Tris gels. Western blot analyses were performed according to standard protocols. All antibodies used were from Cell Signaling: anti-phospho(Thr389)-S6K1 (\#9205), anti-S6K1 (\#2708), anti-phospho(Ser2448)-mTOR (\#2971), anti-mTOR (\#2972), anti-Raptor (\#2280), anti-GAPDH (\#2118).

2.6. Blood and urine measurements {#sec2.6}
---------------------------------

Urine 3-methylhistidine (3MH) was measured as previously described in Ref. [@bib12]. Serum osteocalcin levels were measured using an ELISA assay as previously described in Ref. [@bib13].

2.7. Statistics {#sec2.7}
---------------

All data presented as mean ± SEM. Statistical analyses were performed using unpaired, two-tailed Student\'s test for comparison between two groups and ANOVA tests for experiments involving more than two groups.

3. Results {#sec3}
==========

3.1. Osteocalcin is necessary to maintain muscle mass in adult mice {#sec3.1}
-------------------------------------------------------------------

The recent identification of osteocalcin as a regulator of muscle function during exercise [@bib7] raised the question of whether this hormone regulates any other aspect of muscle biology. This question is also prompted by the fact that circulating osteocalcin levels plummet with age [@bib7].

One of the most common manifestations of aging in muscle is the decrease in muscle mass and/or strength. To test whether osteocalcin is a regulator of muscle mass in adult mice, we analyzed the weight of hindlimb muscles (soleus, EDL, gastrocnemius and quadriceps) in 6-month-old *Ocn*−/− and WT littermates. Because osteocalcin promotes testosterone synthesis specifically in testes but not in ovaries, *Ocn*−/− male mice have lower testosterone levels than WT littermates [@bib9]. Given the influence of testosterone in muscle mass [@bib14] and to avoid this confounding factor all experiments were performed in female mice. These investigations revealed the existence of a significant decrease in the weight of soleus and gastrocnemius muscles and overall a decrease in body weight in *Ocn*−/− mice when compared to WT littermates ([Figure 1](#fig1){ref-type="fig"}A,B). This decrease in muscle mass in *Ocn*−/− mice was explained, at least in part, by a decrease in the cross-section area of the myofibers ([Figure 1](#fig1){ref-type="fig"}C). Since aging can decrease muscle strength we also analyzed this parameter in 12 month-old *Ocn*−/− mice. However, muscle strength measured as the peak amount of force applied by a mouse in grasping a pull bar, was the same in 12-month-old *Ocn*−/− and WT littermates ([Figure 1](#fig1){ref-type="fig"}D). This result suggests that osteocalcin favors maintenance of muscle mass but does not affect muscle strength in a measurable manner in older mice.

3.2. Osteocalcin signaling in myofibers is necessary to maintain muscle mass in older mice {#sec3.2}
------------------------------------------------------------------------------------------

The observation that osteocalcin is necessary to maintain muscle mass in adult mice raised the question as to whether this function of osteocalcin occurs following its signaling through its only identified receptor, GPRC6A [@bib9]. When analyzed at 12 months of age, mice lacking *Gprc6a* in all cells (*Gprc6a*−/−) showed a significant decrease in muscle and body weight ([Figure 2](#fig2){ref-type="fig"}A,B). Because *Gprc6a* is expressed in myofibers and osteocalcin signals through this receptor to regulate muscle function during exercise [@bib7], we next tested whether older mice lacking *Gprc6a* specifically in myofibers (*Gprc6a*~*Mck*~−/−) presented any abnormality in the weight of their hindlimb muscles. The specificity and efficiency of *Mck*-Cre-mediated *Gprc6a* inactivation in *Gprc6a*~*Mck*~−/− mice has been previously reported [@bib7]. At 12 months of age, *Gprc6a*~*Mck*~−/− mice showed a significant decrease in muscle weight when compared to control littermates, although their body weight was normal ([Figure 2](#fig2){ref-type="fig"}C,D). This latter result indicates that osteocalcin regulates muscle mass independently of its effect on energy metabolism [@bib7], [@bib15]. That a similar decrease in muscle weight was observed in 12-month-old compound mutant mice lacking one allele of *Osteocalcin* and one allele of *Gprc6a* specifically in myofibers (*Ocn*+/−;*Gprc6a*~*Mck*~+/−) ([Figure 2](#fig2){ref-type="fig"}E), provide a direct genetic evidence that osteocalcin is the main ligand of GPRC6A in myofibers responsible of its regulation of muscle mass.

3.3. Osteocalcin favors protein synthesis in myotubes {#sec3.3}
-----------------------------------------------------

In an effort to understand the molecular bases of osteocalcin regulation of muscle mass in mice we tested whether osteocalcin regulates muscle protein synthesis or breakdown, because a decrease in muscle protein turnover has been previously associated with a loss of muscle mass [@bib5], [@bib16], [@bib17], [@bib18].

Urinary elimination of 3MH, a byproduct of the degradation of structural proteins in muscle and a biomarker of protein breakdown [@bib19], was similar in *Ocn*−/− and WT mice thus ruling out that osteocalcin regulates protein degradation in muscle ([Figure 3](#fig3){ref-type="fig"}A). That osteocalcin increased in a dose-dependent manner incorporation of ^3^H-tyrosine into proteins of WT but not *Gprc6a*−/− myotubes, suggests that osteocalcin favors protein synthesis in these cells ([Figure 3](#fig3){ref-type="fig"}B--C). The importance of the mTOR complex for protein synthesis led us to ask whether the ability of osteocalcin to favor protein synthesis in myofibers relies in part on the activation of this complex [@bib16], [@bib20]. We observed that osteocalcin induced phosphorylation of S6K1, an mTOR target protein, at Thr389 in WT myotubes ([Figure 3](#fig3){ref-type="fig"}C). This effect was abolished by Torin1, an inhibitor of mTOR signaling, or by the inactivation of the regulatory-associated protein of mTOR (Raptor) ([Figure 3](#fig3){ref-type="fig"}D,E). Taken together these data indicate that osteocalcin promotes protein synthesis in myotubes. This function of osteocalcin signaling in myofibers can explain why this hormone is necessary for the maintenance of muscle mass in aging mice.

3.4. Exogenous osteocalcin is sufficient to increase muscle mass in older mice {#sec3.4}
------------------------------------------------------------------------------

The fact that osteocalcin signaling in myofibers is necessary to maintain muscle mass in older mice and that its levels decrease dramatically in mice during aging, immediately raises the following question: Can exogenous osteocalcin increase muscle mass in older mice? To answer this question we implanted osmotic mini-pumps that delivered subcutaneously recombinant mouse uncarboxylated osteocalcin (osteocalcin) for 28 days (90 ng/h) to 9-month-old WT mice that have already low osteocalcin circulating levels [@bib7]. This chronic delivery of osteocalcin increased significantly osteocalcin circulating levels and muscle weight in 10-month-old mice ([Figure 4](#fig4){ref-type="fig"}A,B). This was explained in part by an increase in the cross-section area of the muscle fibers ([Figure 4](#fig4){ref-type="fig"}C). Muscle strength was the same in vehicle- and osteocalcin-treated mice ([Figure 4](#fig4){ref-type="fig"}D). These results indicate that exogenous osteocalcin has the ability to increase muscle mass in older mice.

4. Discussion {#sec4}
=============

This study reveals that the bone-derived hormone osteocalcin is necessary to maintain muscle mass in older mice in part because it promotes protein synthesis in myotubes. Furthermore, exogenous osteocalcin is sufficient to increase muscle mass in aging mice.

During aging the loss of muscle mass is believed to be due in part to a progressive decrease in the myofibers cross-section area. Several mechanisms have been proposed to explain this phenomenon [@bib21]. Those include age-related intrinsic changes in muscle properties, age-related decrease in physical activity and in the circulating levels of anabolic hormones and growth factors [@bib22], [@bib23], [@bib24]. The fact that osteocalcin positively regulates exercise capacity and that its levels decrease sharply during aging [@bib7] raised the prospect that osteocalcin may regulate muscle mass. By analyzing mutant mice lacking *Osteocalcin* or its receptor, *Gprc6a*, specifically in myofibers we have shown here that osteocalcin signaling in myofibers is necessary to maintain muscle mass in mice as they age. The fact that this regulation of muscle mass by osteocalcin signaling in myofibers cannot be detected in young mice [@bib7] indicates that other mechanisms besides osteocalcin signaling are at work to maintain muscle mass in young mice. Circulating osteocalcin decreases drastically with age. As such, we also show here that administration of exogenous osteocalcin to older mice increases muscle mass and the myofiber cross-section area. Thus, based on these results it appears that osteocalcin signaling in myofibers is both necessary and sufficient to maintain muscle mass in older mice. While muscle mass was consistently decreased in the larger muscle types analyzed the phenotype was less consistent in small muscle types. This can be explained, in part by the technical difficultly of dissecting small muscles, such as the soleus with precision. However, this observation also intimates the existence of other mechanisms that work with osteocalcin to dictate muscle mass in young and older mice.

The maintenance of muscle mass depends on the balance of anabolic (protein synthesis) and catabolic (muscle breakdown) events which together determine the levels of muscle proteins. We failed to record any influence of osteocalcin on protein breakdown in muscle. In contrast we observed that osteocalcin signaling in myofibers favors protein synthesis. Other muscle anabolic hormones activate the PI3K/Akt/mTOR pathway to stimulate protein synthesis and muscle hypertrophy [@bib25]. Consistent with this notion and with the fact that osteocalcin is necessary and sufficient to stimulate Akt phosphorylation in muscle during exercise [@bib7], we show here that osteocalcin promotes protein synthesis in mouse myotubes and that this function requires activation of the mTOR pathway, presumably through the activation of Akt. This mode of action of osteocalcin in myofibers is reminiscent of its action in pancreatic islets, Leydig cells of the testes and the brain where is favors protein synthesis and/or cell proliferation [@bib9], [@bib26].

The study of the mechanisms underlying age-related muscle loss aims at identifying targets for drug discovery and for the development of novel and efficient treatments to combat muscle wasting [@bib21]. Classical physiology experiments have revealed that exposure of old muscle to the blood of young mouse restored the regenerative potential of muscle that was impaired with aging, suggesting that changes in circulating factors may be responsible for the deleterious effect of aging on muscle mass [@bib27], [@bib28], [@bib29]. The recent discovery that osteocalcin levels plummet early in life in mice, monkeys and humans and the fact that this hormone regulates muscle function during exercise and muscle mass as mice age identify this hormone as a promising candidate for the treatment of muscle wasting.
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![**Osteocalcin is necessary to maintain muscle mass in adult mice.** (**A**) Weight of hindlimb muscles and (**B**) body weight in 6 month-old *Ocn*−/− female mice and WT littermates. (**C**) Representative histology and measurement of the cross section area (CSA) of the muscle fibers in 6 month-old *Ocn*−/− female mice and WT littermates. (**D**) Muscle strength determined as the maximal grip force in 12 month-old *Ocn*−/− female mice and WT littermates.](gr1){#fig1}

![**Osteocalcin signaling in myofibers is necessary to maintain muscle mass in older mice.** (**A**) Weight of hindlimb muscles and (**B**) body weight in 12 month-old *Gprc6a*−/− female mice and WT littermates. (**C**) Weight of hindlimb muscles and (**D**) body weight in 12 month-old *Gprc6a*~*Mck*~−/− female mice and WT littermates. (**E**) Weight of hindlimb muscles and (**F**) body weight in 12 month-old compound mutant mice *Ocn*+/−;*Gprc6a*~*Mck*~+/− female mice and control littermates (control group includes WT, *Gprc6af/f*, *Gprc6af/*+ and *Mck-Cre* transgenic mice).](gr2){#fig2}

![**Osteocalcin increases protein synthesis in WT myotubes.** (**A**) Urine levels of 3-methylhistidine (3MH) in *Ocn*−/− female mice and WT littermates. (**B**) Protein synthesis in WT mouse myotubes as measured by ^3^H-Tyrosine incorporation into cellular protein and in (**C**) *Gprc6a*−/− myotubes treated for 2 h with different dose of osteocalcin (Ocn). (**D**) Phosphorylation of S6K1 in WT mouse myotubes treated for 30 min with different dose of Ocn. (**E**) Phosphorylation of S6K1 in WT and *raptor*−/− mouse myotubes treated for 30 min with Ocn (10 ng/ml). (**F**) Phosphorylation of mTOR and S6K1 in WT mouse myotubes treated for 30 min with Ocn (10 ng/ml) in the presence or absence of the mTOR inhibitor Torin 1.](gr3){#fig3}

![**Exogenous osteocalcin is sufficient to increase muscle mass in older mice.** (**A**) Weight of hindlimb muscles and (**B**) body weight of 10 month-old WT female mice receiving vehicle or osteocalcin (Ocn) for 28 days. (**C**) Representative histology and measurement of the cross section area (CSA) of the muscle fibers in 10 month-old WT female mice receiving vehicle or Ocn for 28 days. (**D**) Circulating Ocn levels in 10 month-old WT female mice receiving vehicle or Ocn for 28 days. (**E**) Muscle strength determined as the maximal grip force in 10 month-old WT female mice receiving vehicle or Ocn for 28 days.](gr4){#fig4}
